AI Summary
✦ ClarthaValuation Metrics
Trading 30.5% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.13). Confidence: 76%.
Live forward EPS implies next-12-month EPS of ₹10.60. Applying the stock's normalized valuation corridor produces a fair range of ₹292.03 to ₹452.83, with base value near ₹351.39 (+24.4% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹10.60
Forward P/E
26.7x
Base Fair Value
₹351.39
Fair Range
₹292.03 - ₹452.83
Upside To Base
+24.4%
Estimate Source
Live forward EPS
Growth Estimate
+20.6%
5Y Average
36.95
Current
43.27
Overvalued
42.72
Undervalued
27.55
5Y Average
21.44
Current
25.11
Overvalued
25.73
Undervalued
17.09
5Y Average
5.93
Current
6.95
Overvalued
7.12
Undervalued
4.73
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
RAINBOW CHILDRENS MED LTD RAINBOWHospitals & Diagnostic Centres | +33.2% | 15.7% | 53.4x Undervalued | -27% vs avg | +0.1% |
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.1x Undervalued | -21% vs avg | +9.4% |
THYROCARE TECH LTD THYROCAREHospitals & Diagnostic Centres | +24.3% | 20.1% | 59.0x Undervalued | -20% vs avg | +38.2% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 54.5x Undervalued | -26% vs avg | +12.8% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 46.9x Undervalued | -36% vs avg | +1.3% |
NEPHROCARE HEALTH SERV L NEPHROPLUSHospitals & Diagnostic Centres | +21.2% | 7.7% | 87.3x Premium | +19% vs avg | +48.1% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 69.7x Fair | -5% vs avg | +6.9% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 160.0x Premium | +117% vs avg | +11.4% |
PARK MEDI WORLD LIMITED trades at a discount (43.3x vs peer avg 73.6x), suggesting potential undervaluation relative to the Hospitals & Diagnostic Centres cohort. Peers include RAINBOW CHILDRENS MED LTD, METROPOLIS HEALTHCARE LTD, THYROCARE TECH LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹34 CrJun 2026Latest net profit
₹1.08 CrJun 2026Latest EPS
₹0.03Jun 2026Net margin
3.8%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales + | 22.76 | 23.26 | 22.97 | 32.69 | 45.87 | 27.43 | 33.53 |
| Expenses + | 18.09 | 15.37 | 12.62 | 17.39 | 27.85 | 22.66 | 32.25 |
| Operating Profit | 4.67 | 7.89 | 10.35 | 15.30 | 18.02 | 4.77 | 1.28 |
| OPM % | 20.52% | 33.92% | 45.06% | 46.80% | 39.28% | 17.39% | 3.82% |
| Other Income + | 0.31 | 0.98 | 0.20 | 0.28 | 5.52 | 8.27 | 4.67 |
| Interest | 3.14 | 3.17 | 3.30 | 3.43 | 3.61 | 2.42 | 0.86 |
| Depreciation | 1.30 | 1.33 | 1.16 | 1.16 | 1.18 | 1.01 | 3.38 |
| Profit before tax | 0.54 | 4.37 | 6.09 | 10.99 | 18.75 | 9.61 | 1.71 |
| Tax % | 66.67% | 20.37% | 19.70% | 22.11% | 22.40% | 10.51% | 36.26% |
| Net Profit + | 0.18 | 3.48 | 4.90 | 8.55 | 14.56 | 8.61 | 1.08 |
| EPS in Rs | 0.01 | 0.09 | 0.13 | 0.22 | 0.34 | 0.20 | 0.03 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation